These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21917977)

  • 1. Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.
    Leveille S; Goulet ML; Lichty BD; Hiscott J
    J Virol; 2011 Dec; 85(23):12160-9. PubMed ID: 21917977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.
    Wongthida P; Diaz RM; Pulido C; Rommelfanger D; Galivo F; Kaluza K; Kottke T; Thompson J; Melcher A; Vile R
    Hum Gene Ther; 2011 Nov; 22(11):1343-53. PubMed ID: 21366404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.
    Wongthida P; Diaz RM; Galivo F; Kottke T; Thompson J; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):150-8. PubMed ID: 20959810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
    Willmon C; Diaz RM; Wongthida P; Galivo F; Kottke T; Thompson J; Albelda S; Harrington K; Melcher A; Vile R
    Mol Ther; 2011 Jan; 19(1):140-9. PubMed ID: 20978474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
    Lemay CG; Rintoul JL; Kus A; Paterson JM; Garcia V; Falls TJ; Ferreira L; Bridle BW; Conrad DP; Tang VA; Diallo JS; Arulanandam R; Le Boeuf F; Garson K; Vanderhyden BC; Stojdl DF; Lichty BD; Atkins HL; Parato KA; Bell JC; Auer RC
    Mol Ther; 2012 Sep; 20(9):1791-9. PubMed ID: 22760544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.
    Qiao J; Wang H; Kottke T; Diaz RM; Willmon C; Hudacek A; Thompson J; Parato K; Bell J; Naik J; Chester J; Selby P; Harrington K; Melcher A; Vile RG
    Gene Ther; 2008 Apr; 15(8):604-16. PubMed ID: 18305577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fusogenic vesicular stomatitis virus combined with natural killer T cell immunotherapy controls metastatic breast cancer.
    Nelson A; McMullen N; Gebremeskel S; De Antueno R; Mackenzie D; Duncan R; Johnston B
    Breast Cancer Res; 2024 May; 26(1):78. PubMed ID: 38750591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen processing of vesicular stomatitis virus in situ. Interdigitating dendritic cells present viral antigens independent of marginal dendritic cells but fail to prime CD4(+) and CD8(+) T cells.
    Ciavarra RP; Greene AR; Horeth DR; Buhrer K; van Rooijen N; Tedeschi B
    Immunology; 2000 Dec; 101(4):512-20. PubMed ID: 11122455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.
    Kim DS; Dastidar H; Zhang C; Zemp FJ; Lau K; Ernst M; Rakic A; Sikdar S; Rajwani J; Naumenko V; Balce DR; Ewanchuk BW; Tailor P; Yates RM; Jenne C; Gafuik C; Mahoney DJ
    Nat Commun; 2017 Aug; 8(1):344. PubMed ID: 28839138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the Impact of Oncolytic Vesicular Stomatitis Virus on the Trafficking, Phenotype, and Antigen Presentation Potential of Neutrophils and Their Ability to Acquire a Non-Structural Viral Protein.
    Stegelmeier AA; Chan L; Mehrani Y; Petrik JJ; Wootton SK; Bridle B; Karimi K
    Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32882969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
    Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
    Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.
    Janelle V; Langlois MP; Lapierre P; Charpentier T; Poliquin L; Lamarre A
    Mol Ther; 2014 Jun; 22(6):1198-1210. PubMed ID: 24590047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
    Wang J; Saffold S; Cao X; Krauss J; Chen W
    J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.
    Shen W; Patnaik MM; Ruiz A; Russell SJ; Peng KW
    Blood; 2016 Mar; 127(11):1449-58. PubMed ID: 26712908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
    Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
    Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.
    Rommelfanger DM; Compte M; Grau MC; Diaz RM; Ilett E; Alvarez-Vallina L; Thompson JM; Kottke TJ; Melcher A; Vile RG
    Mol Ther; 2013 Feb; 21(2):348-57. PubMed ID: 23011032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.